ArticleActa neurologica Belgica2026
Construction of a recurrence risk prediction model for benign paroxysmal positional vertigo.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo investigate factors associated with recurrence in patients with benign paroxysmal positional vertigo (BPPV), develop a recurrence risk prediction model, and further evaluate the incremental value of vestibular evoked myogenic potential (VEMP) parameters in improving model predictive performance.
methodsIn this retrospective study, patients with BPPV treated with standardized canalith repositioning maneuvers at Haicang Hospital of Xiamen between January 2022 and December 2024 were included. Demographic data, comorbidities, self-rating anxiety scale (SAS) scores, pittsburgh sleep quality index (PSQI) scores, VEMP parameters, and follow-up information were extracted. Univariable and multivariable logistic regression analyses were conducted to determine factors associated with recurrence, and a recurrence prediction model was developed accordingly. Model discrimination, calibration, and clinical utility were evaluated using receiver operating characteristic (ROC) curve analysis, area under the receiver operating characteristic curve (AUC), bias-corrected calibration curves, the Hosmer-Lemeshow goodness-of-fit test, and decision curve analysis (DCA).
resultsA total of 257 patients with BPPV were included, of whom 64 (24.9%) experienced recurrence during follow-up. Multivariable logistic regression analysis identified diabetes mellitus, hypertension, abnormal ocular vestibular evoked myogenic potential (oVEMP), PSQI score, and SAS score as independent factors associated with BPPV recurrence. The model incorporating these variables showed good discrimination, with an AUC of 0.796 (95% CI, 0.734-0.857), which was significantly higher than that of the model excluding oVEMP abnormality (AUC = 0.736; 95% CI, 0.669-0.804; P = 0.021). The model demonstrated good calibration according to the Hosmer-Lemeshow test (P = 0.270). DCA indicated a favorable net benefit across threshold probabilities ranging from 0.20 to 0.60. Internal validation using bootstrap resampling yielded an optimism-corrected AUC of 0.777 (95% CI, 0.722-0.843).
conclusionDiabetes mellitus, hypertension, PSQI score, SAS score, and abnormal oVEMP are associated with the recurrence of BPPV. The prediction model developed from these factors exhibited good discrimination and calibration. This model may facilitate risk‑stratification and inform individualized management considerations for patients with BPPV.
Indexed as
Identifiers
42744978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.